{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:01:55Z","timestamp":1786982515696,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01267-8","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T07:02:51Z","timestamp":1724914971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer"],"prefix":"10.1007","volume":"15","author":[{"given":"Ying","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengmao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"1267_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin."},{"key":"1267_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134:783\u201391. https:\/\/doi.org\/10.1097\/CM9.0000000000001474.","journal-title":"Chin Med J (Engl)"},{"key":"1267_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343.pub4","author":"SL Coleridge","year":"2019","unstructured":"Coleridge SL, Bryant A, Lyons TJ, Goodall RJ, Kehoe S, Morrison J. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2019. https:\/\/doi.org\/10.1002\/14651858.CD005343.pub4.","journal-title":"Cochrane Database Syst Rev."},{"key":"1267_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2019.02.014","volume":"113","author":"A Coosemans","year":"2019","unstructured":"Coosemans A, Vankerckhoven A, Baert T, Boon L, Ruts H, Riva M, Blagden S, Delforge M, Concin N, Mirza MR, Ledermann JA, du Bois A, Vergote I. Combining conventional therapy with immunotherapy: a risky business? Eur J Cancer. 2019;113:41\u20134. https:\/\/doi.org\/10.1016\/j.ejca.2019.02.014.","journal-title":"Eur J Cancer"},{"key":"1267_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1470-2045(20)30178-9","volume":"21","author":"RT Penson","year":"2020","unstructured":"Penson RT. Platinum-sensitive ovarian cancer: liminal advances. Lancet Oncol. 2020;21:614\u20135. https:\/\/doi.org\/10.1016\/S1470-2045(20)30178-9.","journal-title":"Lancet Oncol."},{"key":"1267_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","volume":"22","author":"S Pignata","year":"2021","unstructured":"Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F, Investigators MIbM-OE-o. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021;22:267\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(20)30637-9.","journal-title":"Lancet Oncol."},{"key":"1267_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00008","volume":"2","author":"NYL Ngoi","year":"2018","unstructured":"Ngoi NYL, Tay D, Heong V, Thian YL, Ong PY, Ow SGW, Jeyasekharan AD, Lim YW, Lim SE, Lee SC, Ng J, Low JJH, Ilancheran A, Koh SZL, Tan DSP. Reversal of bowel obstruction with platinum-based chemotherapy and olaparib in recurrent, short platinum-free interval, RAD51C germline mutation-associated ovarian cancer. JCO Precis Oncol. 2018;2:1\u20138. https:\/\/doi.org\/10.1200\/PO.18.00008.","journal-title":"JCO Precis Oncol."},{"key":"1267_CR8","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bjc.2017.478","volume":"118","author":"B Han","year":"2018","unstructured":"Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, Lu Y, Shi Y, Wang Z, Jiang L, Luo Y, Zhang Y, Huang C, Li Q, Wu G. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118:654\u201361. https:\/\/doi.org\/10.1038\/bjc.2017.478.","journal-title":"Br J Cancer."},{"key":"1267_CR9","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4:1569\u201375. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3039.","journal-title":"JAMA Oncol."},{"key":"1267_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.31083\/j.fbl2704125","volume":"27","author":"S Chen","year":"2022","unstructured":"Chen S, Gao Y, Zhu P, Wang X, Zeng L, Jin Y, Zhi X, Yang H, Zhou P. Anti-cancer drug anlotinib promotes autophagy and apoptosis in breast cancer. Front Biosci (Landmark Ed). 2022;27:125. https:\/\/doi.org\/10.31083\/j.fbl2704125.","journal-title":"Front Biosci (Landmark Ed)."},{"key":"1267_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280\u2013304. https:\/\/doi.org\/10.3322\/caac.21559.","journal-title":"CA Cancer J Clin."},{"issue":"Suppl 1","key":"1267_CR12","doi-asserted-by":"publisher","first-page":"i63","DOI":"10.1093\/annonc\/mdw079","volume":"27","author":"E Pujade-Lauraine","year":"2016","unstructured":"Pujade-Lauraine E, Combe P. Recurrent ovarian cancer. Ann Oncol. 2016;27(Suppl 1):i63\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdw079.","journal-title":"Ann Oncol."},{"key":"1267_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell."},{"key":"1267_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/CCO.0b013e32835b651e","volume":"25","author":"P Hainaut","year":"2013","unstructured":"Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol. 2013;25:50\u20131. https:\/\/doi.org\/10.1097\/CCO.0b013e32835b651e.","journal-title":"Curr Opin Oncol."},{"key":"1267_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","volume":"78","author":"YY Syed","year":"2018","unstructured":"Syed YY. Anlotinib: first global approval. Drugs. 2018;78:1057\u201362. https:\/\/doi.org\/10.1007\/s40265-018-0939-x.","journal-title":"Drugs."},{"key":"1267_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010162","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Wang X, Chen Z, Zhou L, Di X, Fan P, He Z. Anlotinib suppressed ovarian cancer progression via inducing G2\/M phase arrest and apoptosis. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm12010162.","journal-title":"J Clin Med"},{"key":"1267_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073765","author":"F Lopes-Coelho","year":"2021","unstructured":"Lopes-Coelho F, Martins F, Pereira SA, Serpa J. Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22073765.","journal-title":"Int J Mol Sci"},{"key":"1267_CR18","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039\u201345. https:\/\/doi.org\/10.1200\/JCO.2012.42.0505.","journal-title":"J Clin Oncol."},{"key":"1267_CR19","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/annonc\/mdx228","volume":"28","author":"A Bamias","year":"2017","unstructured":"Bamias A, Gibbs E, Khoon Lee C, Davies L, Dimopoulos M, Zagouri F, Veillard AS, Kosse J, Santaballa A, Mirza MR, Tabaro G, Vergote I, Bloemendal H, Lykka M, Floquet A, Gebski V, Pujade-Lauraine E. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Ann Oncol. 2017;28:1842\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdx228.","journal-title":"Ann Oncol."},{"key":"1267_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O\u2019Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(17)30279-6.","journal-title":"Lancet Oncol."},{"key":"1267_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ijc.32180","volume":"145","author":"G Wang","year":"2019","unstructured":"Wang G, Sun M, Jiang Y, Zhang T, Sun W, Wang H, Yin F, Wang Z, Sang W, Xu J, Mao M, Zuo D, Zhou Z, Wang C, Fu Z, Wang Z, Duan Z, Hua Y, Cai Z. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer. 2019;145:979\u201393. https:\/\/doi.org\/10.1002\/ijc.32180.","journal-title":"Int J Cancer."},{"key":"1267_CR22","doi-asserted-by":"publisher","first-page":"12389","DOI":"10.18632\/oncotarget.13310","volume":"8","author":"L Rossi","year":"2017","unstructured":"Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, Vici P, Bianco V, Tomao F. Bevacizumab in ovarian cancer: a critical review of phase III studies. Oncotarget. 2017;8:12389\u2013405. https:\/\/doi.org\/10.18632\/oncotarget.13310.","journal-title":"Oncotarget."},{"key":"1267_CR23","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(15)00086-8.","journal-title":"Lancet Oncol."},{"key":"1267_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(15)00064-9","volume":"16","author":"JF Liu","year":"2015","unstructured":"Liu JF, Matulonis UA. Bevacizumab in newly diagnosed ovarian cancer. Lancet Oncol. 2015;16:876\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(15)00064-9.","journal-title":"Lancet Oncol."}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01267-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01267-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01267-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T07:32:35Z","timestamp":1724916755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01267-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1267"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01267-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the ethics committee of the Fourth Hospital of Hebei Medical University (2020166). All procedures were conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and its later amendments. The patients provided their written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"These authors declare that they have no competing interest in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"383"}}